Danazol and prolactin status in patients with endometriosis.
A group of 55 women with endometriosis was studied before and during danazol therapy. An unexpectedly high proportion (36%) had a raised serum prolactin level before treatment which was reduced after 50 days of danazol (before treatment 783 +/- 333 mU/l; on danazol 243 +/- 113 mU/l, P less than 0.001). In contrast patients with normal serum prolactin levels showed no significant drop on danazol therapy. In all patients serum oestradiol was significantly reduced during treatment (before treatment 449 +/- 188 pmol/l; on danazol 207 +/- 117 pmol/l, P less than 0.001). In one patient with hyperprolactinaemia danazol reduced both basal and stimulated prolactin levels, whereas in 5 women with normal prolactin levels we could detect no gross alteration in metoclopramide or TRH stimulated prolactin levels associated with danazol therapy. The possibility that normalisation of raised prolactin levels may be secondary to reduced oestrogens and that patients with endometriosis have an increased sensitivity to oestrogen-induced prolactin secretion is discussed.
D003613:Danazol / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008787:Metoclopramide / Q000494:pharmacology; D011245:Pregnadienes / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D011245:Pregnadienes; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D008787:Metoclopramide; D003613:Danazol